Abrilumab
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) [1].
Product Specifications
CAS Number
1342290-43-0
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/abrilumab.html
Purity
98.35
Solubility
10 mM in DMSO
Smiles
[Abrilumab]
Molecular Weight
(143.8 kDa)
References & Citations
[1]Iris Dotan, et al. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. Med Res Rev|[2]Christopher A Lamb, et al. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. J Crohns Colitis. 2018 Aug 22;12 (suppl_2) :S653-S668.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15239041 1 Vial
Lentiviral mouse Ccdc62 shRNA (UAS) - Lentiviral mouse Ccdc62 shRNA (UAS, RFP) plasmid
Sign In for Pricing
View Details 
MBS6416717-01 0.1 mL
FABP5 (Fatty Acid Binding Protein 5, E-FABP, EFABP, PA-FABP, PAFABP) (AP)
Sign In for Pricing
View Details MBS6416717-02 5x 0.1 mL
FABP5 (Fatty Acid Binding Protein 5, E-FABP, EFABP, PA-FABP, PAFABP) (AP)
Sign In for Pricing
View Details